mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.

2.50
Hdl Handle:
http://hdl.handle.net/10147/243784
Title:
mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.
Authors:
Walsh, S; Flanagan, L; Quinn, C; Evoy, D; McDermott, E W; Pierce, A; Duffy, M J
Affiliation:
UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland.
Citation:
mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. 2012, 21 (2):178-82 Breast
Publisher:
Elsevier
Journal:
Breast (Edinburgh, Scotland)
Issue Date:
Apr-2012
URI:
http://hdl.handle.net/10147/243784
DOI:
10.1016/j.breast.2011.09.008
PubMed ID:
21963359
Abstract:
Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptors (ER), progesterone receptors (PR) and overexpression of HER2. Targeted therapy is currently unavailable for this subgroup of breast cancer patients. mTOR controls cancer cell growth, survival and invasion and is thus a potential target for the treatment of patients with TNBC. Using immunohistochemistry, mTOR and p-mTOR were measured in 89 TNBCs and 99 non-TNBCs. While mTOR expression was confined to tumor cell cytoplasm, p-mTOR staining was located in the nucleus, perinuclear area and in the cytoplasm. Potentially important, was our finding that nuclear p-mTOR was found more frequently in triple-negative than non triple-negative cancers (p < 0.001). These results suggest that mTOR may play a more important role in the progression of TNBC compared to non-TNBC. Based on these findings, we conclude that mTOR may be a new target for the treatment of triple-negative breast cancer.
Item Type:
Other
Language:
en
Keywords:
Breast Neoplasms/metabolism; Receptor, erbB-2/metabolism; Receptors, Estrogen/metabolism; Receptors, Progesterone/metabolism; TOR Serine-Threonine Kinases/metabolism
MeSH:
Breast Neoplasms; Disease Progression; Female; Humans; Immunohistochemistry; Middle Aged; Receptor, erbB-2; Receptors, Estrogen; Receptors, Progesterone; TOR Serine-Threonine Kinases
ISSN:
1532-3080

Full metadata record

DC FieldValue Language
dc.contributor.authorWalsh, Sen_GB
dc.contributor.authorFlanagan, Len_GB
dc.contributor.authorQuinn, Cen_GB
dc.contributor.authorEvoy, Den_GB
dc.contributor.authorMcDermott, E Wen_GB
dc.contributor.authorPierce, Aen_GB
dc.contributor.authorDuffy, M Jen_GB
dc.date.accessioned2012-09-13T09:11:43Z-
dc.date.available2012-09-13T09:11:43Z-
dc.date.issued2012-04-
dc.identifier.citationmTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. 2012, 21 (2):178-82 Breasten_GB
dc.identifier.issn1532-3080-
dc.identifier.pmid21963359-
dc.identifier.doi10.1016/j.breast.2011.09.008-
dc.identifier.urihttp://hdl.handle.net/10147/243784-
dc.description.abstractTriple-negative breast cancer (TNBC) is defined by the absence of estrogen receptors (ER), progesterone receptors (PR) and overexpression of HER2. Targeted therapy is currently unavailable for this subgroup of breast cancer patients. mTOR controls cancer cell growth, survival and invasion and is thus a potential target for the treatment of patients with TNBC. Using immunohistochemistry, mTOR and p-mTOR were measured in 89 TNBCs and 99 non-TNBCs. While mTOR expression was confined to tumor cell cytoplasm, p-mTOR staining was located in the nucleus, perinuclear area and in the cytoplasm. Potentially important, was our finding that nuclear p-mTOR was found more frequently in triple-negative than non triple-negative cancers (p < 0.001). These results suggest that mTOR may play a more important role in the progression of TNBC compared to non-TNBC. Based on these findings, we conclude that mTOR may be a new target for the treatment of triple-negative breast cancer.en_GB
dc.language.isoenen
dc.publisherElsevieren_GB
dc.rightsArchived with thanks to Breast (Edinburgh, Scotland)en_GB
dc.subjectBreast Neoplasms/metabolismen_GB
dc.subjectReceptor, erbB-2/metabolismen_GB
dc.subjectReceptors, Estrogen/metabolismen_GB
dc.subjectReceptors, Progesterone/metabolismen_GB
dc.subjectTOR Serine-Threonine Kinases/metabolismen_GB
dc.subject.meshBreast Neoplasms-
dc.subject.meshDisease Progression-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshMiddle Aged-
dc.subject.meshReceptor, erbB-2-
dc.subject.meshReceptors, Estrogen-
dc.subject.meshReceptors, Progesterone-
dc.subject.meshTOR Serine-Threonine Kinases-
dc.titlemTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.en_GB
dc.typeOtheren
dc.contributor.departmentUCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland.en_GB
dc.identifier.journalBreast (Edinburgh, Scotland)en_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus,the Irish health repository are protected by copyright, with all rights reserved, unless otherwise indicated.